{"id":177359,"date":"2011-07-28T00:00:00","date_gmt":"2011-07-27T22:00:00","guid":{"rendered":"https:\/\/www.bcfi.be\/pioglitazone-actos-lema-recommande-de-nouvelles-precautions-en-raison-dune-faible-augmentation-du-risque-de-cancer-de-la-vessie\/"},"modified":"2026-04-09T17:13:18","modified_gmt":"2026-04-09T15:13:18","slug":"pioglitazone-actos-lema-recommande-de-nouvelles-precautions-en-raison-dune-faible-augmentation-du-risque-de-cancer-de-la-vessie","status":"publish","type":"post","link":"https:\/\/beta.cbip.be\/fr\/pioglitazone-actos-lema-recommande-de-nouvelles-precautions-en-raison-dune-faible-augmentation-du-risque-de-cancer-de-la-vessie\/","title":{"rendered":"Pioglitazone (Actos\u00ae): l\u2019EMA recommande de nouvelles pr\u00e9cautions en raison d\u2019une faible augmentation du risque de cancer de la vessie"},"content":{"rendered":"<div class='tekst'>\n<p> \u00a0<\/p>\n<p> Il a \u00e9t\u00e9 sugg\u00e9r\u00e9&#x002C; sur base d\u2019\u00e9tudes \u00e9pid\u00e9miologiques r\u00e9centes r\u00e9alis\u00e9es aux Etats-Unis et en France&#x002C;\u00a0 que les patients trait\u00e9s par la pioglitazone (Actos\u00ae&#x002C; un antidiab\u00e9tique oral) ont un risque l\u00e9g\u00e8rement accru de d\u00e9velopper un cancer de la vessie [voir \u00ab\u00a0Bon \u00e0 savoir\u00a0\u00bb du 10\/06\/11 ]. Ce risque de cancer de la vessie avait d\u00e9j\u00e0 \u00e9t\u00e9 constat\u00e9 chez le rat dans des \u00e9tudes pr\u00e9cliniques&#x002C; ce qui figure dans le r\u00e9sum\u00e9 des caract\u00e9ristiques du produit.<\/p>\n<p> Le <em>Committee for Medicinal Products for Human Use<\/em> (CHMP) de l\u2019<em>European<\/em> <em>Medicines Agency<\/em> (EMA) a r\u00e9\u00e9valu\u00e9 les donn\u00e9es disponibles \u00e0 ce sujet. Sa conclusion est que la pioglitazone est associ\u00e9e \u00e0 une faible augmentation du risque de cancer de la vessie&#x002C; mais que chez un nombre limit\u00e9 de patients diab\u00e9tiques de type 2&#x002C; la balance b\u00e9n\u00e9fices-risques de la pioglitazone reste n\u00e9anmoins positive. Le CHMP recommande toutefois un certain nombre de pr\u00e9cautions suppl\u00e9mentaires afin de r\u00e9duire cette faible augmentation de risque de cancer de la vessie.<\/p>\n<p> Il est ainsi d\u00e9conseill\u00e9 d\u2019utiliser la pioglitazone chez les patients atteints ou avec des ant\u00e9c\u00e9dents de cancer de la vessie ainsi que chez les patients pr\u00e9sentant une h\u00e9maturie macroscopique non investigu\u00e9e. Comme mentionn\u00e9 dans le R\u00e9pertoire Comment\u00e9 des M\u00e9dicaments&#x002C; la place de la pioglitazone dans la prise en charge du diab\u00e8te de type 2 reste limit\u00e9e et elle ne devrait \u00eatre utilis\u00e9e qu\u2019en troisi\u00e8me intention. [<a href='https:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2011\/07\/news_detail_001311.jsp&#038;murl=menus\/news_and_events\/news_and_events.jsp&#038;mid=WC0b01ac058004d5c1'>www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2011\/07\/news_detail_001311.jsp&#038;murl=menus\/news_and_events\/news_and_events.jsp&#038;mid=WC0b01ac058004d5c1<\/a>]<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0 Il a \u00e9t\u00e9 sugg\u00e9r\u00e9&#x002C; sur base d\u2019\u00e9tudes \u00e9pid\u00e9miologiques r\u00e9centes  [&#8230;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,52],"tags":[20213,20224],"class_list":["post-177359","post","type-post","status-publish","format-standard","hentry","category-actualites","category-2011-fr","tag-import_tags","tag-import_tags-nl"],"_links":{"self":[{"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/posts\/177359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/comments?post=177359"}],"version-history":[{"count":1,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/posts\/177359\/revisions"}],"predecessor-version":[{"id":179933,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/posts\/177359\/revisions\/179933"}],"wp:attachment":[{"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/media?parent=177359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/categories?post=177359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/tags?post=177359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}